Price Hike on Essential Medicines: What Patients Need to Know
Starting April 1, 2026, patients can expect to pay slightly more for critical antibiotics like Meropenem and essential intravenous (IV) fluids, including glucose and sodium chloride. The National Pharmaceutical Pricing Authority (NPPA) has revised the price ceilings for these medications, citing adjustments based on the Wholesale Price Index (WPI).
Meropenem: A Marginal Increase for a Life-Saving Drug
Meropenem, a powerful, last-resort antibiotic used in intensive care units for severe bacterial infections, will witness a modest price increase. The 500 milligram injection is capped at Rs 851.43, up from Rs 845.94, although the 1,000 milligram version will cost Rs 1,121.96, compared to Rs 1114.72. These prices exclude Goods and Services Tax (GST). The revision, representing a 0.64956 percent increase, primarily impacts bulk purchases.
This price control is significant as Meropenem is crucial for treating conditions like septicaemia, hospital-acquired pneumonia and infections in immunocompromised patients. The government’s intervention aims to ensure financial accessibility to this life-saving medication.
IV Fluids Also Affected
The price adjustments aren’t limited to antibiotics. IV fluids, vital for hydration and medication delivery, are also subject to revised ceilings. A 1000 ml pack of 5% glucose injection (in a non-glass container with special features) will now cost Rs 97.40, up from Rs 95.10. The 500 ml pack is capped at Rs 84.24. Glucose with sodium chloride (5% + 0.9%) will be priced at Rs 102.34 for 1000 ml and Rs 87.58 for 500 ml. Sodium chloride (0.9%) injections will range from Rs 43.07 for 100 ml to Rs 100.87 for 1000 ml.
What This Means for Manufacturers and Patients
Manufacturers currently selling these drugs above the new ceiling prices are legally obligated to lower their prices immediately. Those with existing prices below the old ceiling are permitted to increase them, following a specific formula outlined in the Drugs Prices Control Order, 2013. Non-compliance can lead to penalties, including the need to deposit overcharged amounts with interest, as per the Essential Commodities Act, 1955.
The NPPA’s actions apply mainly to formulations packaged in non-glass containers with special features, produced by major companies like B Braun Medical, Baxter India, Fresenius Kabi, and Otsuka Pharmaceutical India.
The Broader Trend: Pharmaceutical Price Regulation in India
This revision is part of a larger pattern of pharmaceutical price regulation in India, overseen by the NPPA. The authority routinely adjusts prices of essential medicines based on the WPI to balance affordability and manufacturer viability. Similar revisions impacting around 400 essential drugs were implemented in 2025, with an increase of 1.74 percent.
In January 2023, the NPPA revised prices for 128 formulations, including painkillers and other antibiotics, signaling a continued commitment to price control. These adjustments, while often marginal, collectively impact healthcare costs for millions of Indians.
Did you know?
The National List of Essential Medicines (NLEM) is the foundation for price control in India. The NPPA regulates the prices of drugs included in this list.
FAQ
Q: When do the new prices come into effect?
A: April 1, 2026.
Q: What is the Wholesale Price Index (WPI)?
A: The WPI measures the change in prices of goods in the economy and is used by the NPPA to adjust drug prices annually.
Q: Are these prices inclusive of GST?
A: No, the prices quoted are exclusive of Goods and Services Tax.
Q: What happens if a manufacturer doesn’t comply with the new price ceilings?
A: They may be required to deposit the overcharged amount along with interest.
Q: Which companies are primarily affected by the IV fluid price revisions?
A: B Braun Medical, Baxter India, Fresenius Kabi, and Otsuka Pharmaceutical India are among the major manufacturers impacted.
Pro Tip: Always check the manufacturing date and expiry date of medications, especially when purchasing in bulk.
Stay informed about changes in pharmaceutical pricing and their potential impact on your healthcare expenses. Explore more articles on healthcare policy and drug affordability on our website.
